MASLD/MASH Biomarkers: FIB-4, ELF, PRO-C3, MRI-PDFF

Introduction: Why Biomarkers Dictate MASH Drug Discovery

Non-Alcoholic Fatty Liver Disease (NAFLD) has been redefined globally as Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Consequently, NASH has transitioned to MASH. For the background of this renaming and a side-by-side comparison of the four frameworks (NAFLD / MAFLD / MASLD / MetALD), see MASLD vs MAFLD vs NASH/MASH: Nomenclature & Criteria Guide.

The history of MASH/NASH drug development has been a continuous battle against the invasive gold standard: the liver biopsy. The central challenges are: "How do we reduce painful biopsies fraught with sampling errors?" and "How do we accurately identify patients with clinically significant fibrosis (F2-F3) who truly need pharmacotherapy?" To solve these, the development of Non-Invasive Tests (NITs) has accelerated explosively.

This article details the specific serum and imaging biomarkers currently deployed in clinical trials and explains how integrating them into preclinical animal models dramatically improves translational success.

---

1. Major Serum Biomarkers (Blood-Based Composite Scores)

These are blood-based composite scores widely used in routine clinical practice and for clinical trial screening.

① FIB-4 Index (Fibrosis-4)

• Formula: Calculated using Age, AST, ALT, and Platelet count.
• Roles & Features: The most widespread first-line screening tool. Because it is simple and essentially "free" to calculate from standard lab values, it acts as the highly effective gatekeeper to identify MASLD patients holding a high risk for advanced fibrosis (≥F3). For the formula, age-stratified cutoffs (35-65: 1.3/2.67, ≥65: 2.0/2.67), AASLD 2023 / EASL 2024 algorithms, and the FIB-4 + ELF two-step strategy with pitfalls, see the FIB-4 Score Complete Guide.
• Limitations: Prone to false positives in the elderly population and relatively poor at capturing dynamic, short-term therapeutic improvements during treatment.

② ELF Score (Enhanced Liver Fibrosis Score)

• Components: Three direct markers of extracellular matrix (ECM) turnover: Hyaluronic Acid (HA), PIIINP (N-terminal propeptide of type III collagen), and TIMP-1.
• Roles & Features: Because it directly reflects matrix dynamics, it is significantly more robust than FIB-4. Having received De Novo marketing authorization from the FDA in 2021 (DEN200051)¹, it is extensively utilized as a screening and prognostic factor in mid-to-late stage MASH trials. See the ELF Score complete guide for the full formula, clinical cutoffs, and MASH trial operational examples.
• Translational Value: Fluctuations in TIMP-1 and collagen peptides can be readily tracked in mouse MASH models, making the ELF score highly translational.

③ FAST Score (FibroScan-AST)

• Formula: Combines Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP)—both derived from FibroScan®—along with AST.
• Roles & Features: By simultaneously capturing the trio of "Fat, Inflammation, and Fibrosis," it is perfectly positioned to pinpoint patients with "Active MASH." It was notably utilized for patient enrichment and screening in late-phase MASH trials such as MAESTRO-NASH (Resmetirom).

④ Other Emerging Biochemical Markers

• CK-18 (Cytokeratin 18 fragments): A biomarker of hepatocyte apoptosis. It strongly correlates with the degree of hepatocyte ballooning and inflammation in MASH.
• PRO-C3: A specific neo-epitope reflecting the active formation of type III collagen². It is rapidly gaining traction as an acute pharmacodynamic (PD) marker that can detect early responses to anti-fibrotic therapies much faster than histology.

---

2. Major Imaging Biomarkers

While more expensive than blood tests, advanced imaging modalities provide objective, whole-liver assessments of structural and physical changes.

① MRI-PDFF (Proton Density Fat Fraction)

• Mechanism: Uses MRI to accurately quantify the percentage of fat content within the liver.
• Role in MASH: It is the absolute gold standard for assessing "steatosis improvement." In Phase II clinical trials (especially for GLP-1RAs such as Semaglutide and THR-β agonists such as Resmetirom), a relative reduction of ≥30% in MRI-PDFF is a standard primary endpoint.

② MRE (Magnetic Resonance Elastography)

• Mechanism: Uses external acoustic vibrations generated inside an MRI scanner to map the physical "stiffness" (in kPa) of the liver tissue.
• Role in MASH: The most accurate non-invasive modality available to span the entire liver and assess the severity of fibrosis, completely circumventing the sampling error inherent to needle biopsies.

③ VCTE (Vibration-Controlled Transient Elastography / FibroScan®)

• Mechanism: An ultrasound-based, bedside evaluation providing LSM (stiffness) and CAP (steatosis).
• Role in MASH: While slightly less accurate than MRE, its supreme convenience and widespread availability make VCTE the de facto "Standard of Care" screening tool for trial enrollment worldwide. The FDA has further issued a Letter of Intent (2024) supporting VCTE-based LSM as a reasonably likely surrogate endpoint for MASH clinical trials³.

---

3. Translation Between Preclinical (Animal Models) and Clinical Phases

The most common point of failure in MASH drug development is the translational disconnect: "The drug cured the mouse, but failed in the human." To mitigate this, integrating clinical NITs into preclinical designs is paramount.

Integration into Mouse MASH Models (e.g., GAN, CDAHFD diets)

1. Longitudinal Serum Sampling: Instead of relying solely on terminal endpoints, perform micro-sampling during the disease induction and treatment phases to measure HA, TIMP-1, and PRO-C3 alongside ALT over time. This allows investigators to track intra-hepatic fibrogenesis longitudinally "without sacrificing the mouse," scaling perfectly to human trial monitoring.
2. Utilizing Small-Animal MRI/MRE: Advanced CROs and academic institutions now deploy specialized high-field MRIs for rodents. Testing a compound's efficacy by measuring prospectively via MRI-PDFF (fat reduction) or MRE in a preclinical setting allows for a Go/No-Go decision using the exact identical modality that will be used in the Phase II clinical trial.
3. Ground-Truthing via AI Pathology: Demonstrating precisely how fluctuations in serum biomarkers correlate with actual, AI-quantified histopathology (e.g., Sirius Red area fraction, ballooning area) during the preclinical phase provides incredibly powerful supporting data for eventual FDA IND and NDA submissions.

Summary

The landscape of MASLD/MASH drug development has shifted decisively from relying solely on biopsy endpoints to orchestrating a complex, multi-modal strategy combining these advanced serum and imaging Biomarkers (NITs).

Winning the MASH race requires establishing a "Translational Biomarker Strategy" early—deciding precisely how the clinical biomarkers you intend to use in humans will be validated and modeled during the initial preclinical animal studies.

References

1. Siemens Healthineers / FDA. "ELF Test: First Prognostic Blood Test for Advanced Fibrosis Due to NASH." FDA De Novo Authorization (DEN200051), August 24, 2021. (Siemens Press Release) (FDA)

2. Daniels SJ, et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology. 2019;69(3):1075-1086. (PubMed)

3. FDA. Qualification of Liver Stiffness Measurement by VCTE as Reasonably Likely Surrogate Endpoint for MASH Clinical Trials. Letter of Intent, 2024. (FDA Biomarker Qualification Program)